ERBB2 and breast carcinoma: Previous studies found that this method detected targetable HER2 mutations not only in breast cancer LMD but also in non-small cell lung cancer (NSCLC) and upper gastrointestinal cancer in whom the primary tumor biopsy was negative for HER2 [23].